CLINICAL TRIALS PROFILE FOR CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE
✉ Email this page to a colleague
All Clinical Trials for ciprofloxacin hydrochloride; hydrocortisone
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00774280 ↗ | Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen | Completed | Cooperative Study Group A for Hematology | Phase 3 | 2002-05-01 | 1. At the same time of registration, patients will be randomized to one of the two conditioning therapy groups; Arm I (intravenous busulfan plus cyclophosphamide; BuCy) or Arm II (intravenous busulfan plus fludarabine; BuFlu). 2. Randomization will be a stratified permuted-block design. 2.1The patients will be stratified into standard risk vs. high risk group, and related vs. unrelated donor. Standard risk group will be defined as follows: patients with acute leukemia in first remission, CML in chronic phase, and MDS (RA or RARS categories). High risk group will be defined as follows: patients with acute leukemia in relapse or in second or subsequent remission, CML in accelerated or blastic phase, and MDS (CMMoL or RAEB categories). 2.2.Pre-assigned block size is 8. |
NCT00980876 ↗ | A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension | Completed | Pharmagenix Projetos em Medicina Farmacêutica Ltda. | Phase 3 | 2012-04-01 | The objective of this study is to compare the efficacy and safety profiles of the test product containing 2 mg/mL ciprofloxacin hydrochloride associated with 10 mg/mL of hydrocortisone with the reference product Cipro HC®, in patients with acute otitis externa. |
NCT00980876 ↗ | A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension | Completed | Farmoquimica S.A. | Phase 3 | 2012-04-01 | The objective of this study is to compare the efficacy and safety profiles of the test product containing 2 mg/mL ciprofloxacin hydrochloride associated with 10 mg/mL of hydrocortisone with the reference product Cipro HC®, in patients with acute otitis externa. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ciprofloxacin hydrochloride; hydrocortisone
Condition Name
Clinical Trial Locations for ciprofloxacin hydrochloride; hydrocortisone
Clinical Trial Progress for ciprofloxacin hydrochloride; hydrocortisone
Clinical Trial Phase
Clinical Trial Sponsors for ciprofloxacin hydrochloride; hydrocortisone
Sponsor Name
Sponsor Name for ciprofloxacin hydrochloride; hydrocortisone | |
Sponsor | Trials |
Haining Health-Coming Biotech Co., Ltd. | 1 |
Cooperative Study Group A for Hematology | 1 |
Pharmagenix Projetos em Medicina Farmacêutica Ltda. | 1 |
[disabled in preview] | 0 |
This preview shows a limited data set Subscribe for full access, or try a Trial |